Dermapharm Holding SE's Total Assets for the quarter that ended in Mar. 2026 was €2,273 Mil.
Warning Sign:
If a company builds assets at 14.6% a year, faster than its revenue growth rate of 8% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Dermapharm Holding SE's average Total Assets Growth Rate was 1.30% per year.
During the past 3 years, the average Total Assets Growth Rate was 16.60% per year.
During the past 5 years, the average Total Assets Growth Rate was 14.60% per year.
During the past 10 years, the average Total Assets Growth Rate was 24.20% per year.
During the past 13 years, Dermapharm Holding SE's highest 3-Year average Total Assets Growth Rate was 44.50%. The lowest was -3.80%. And the median was 17.60%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Dermapharm Holding SE's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Dermapharm Holding SE Total Assets Related Terms
Dermapharm Holding SE Total Assets Historical Data
* Premium members only.
The historical data trend for Dermapharm Holding SE's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Dermapharm Holding SE's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dermapharm Holding SE (CHIX:DMPD) has a Total Assets of €2,273 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Dermapharm Holding SE and its competitors.
Is Dermapharm Holding SE's Total Assets too high?
Dermapharm Holding SE's current Total Assets is €2,273 Mil. Overall, Dermapharm Holding SE has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's Total Assets compare to ZTS and UTHR?
Dermapharm Holding SE's Total Assets of €2,273 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Dermapharm Holding SE and its competitors. Dermapharm Holding SE's current Total Assets is €2,273 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Dermapharm Holding SE (CHIX:DMPD) has a current Total Assets of €2,273 Mil. The stock's GF Value™ is €38.59, compared to a current price of €46.18 — trading 19.7% above its estimated fair value. The current Total Assets is €2,273 Mil. Dermapharm Holding SE's overall GF Score™ is 80/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current Total Assets is €2,273 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued.
The current stock price of €46.18 is trading 19.7% above its estimated GF Value™ of €38.59.
Key valuation signals for CHIX:DMPD:
Total Assets: €2,273 Mil
GF Value™: €38.59 vs. price of €46.18 (19.7% above fair value)
No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
80GF Score
Get the complete analysis for CHIX:DMPD
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DMPD has been successfully added to your 
